Jurkat T-cell proliferation

Jurkat T-cell proliferation refers to the rapid mitotic expansion of the Jurkat cell line, an immortalized lineage of human T lymphocytes originally derived from a patient with T-cell acute lymphoblastic leukemia (T-ALL) [1]. In pharmacological research, this process is not a single molecular target but rather a phenotypic readout used in cell-based assays to evaluate the potency of immunosuppressive or anti-neoplastic agents [2]. Proliferation in Jurkat cells is driven by the activation of complex signaling networks, including the T-cell receptor (TCR) pathway, the PI3K/Akt/mTOR axis, and the MAPK/ERK cascade [3]. Because Jurkat cells often harbor mutations in tumor suppressor genes like PTEN, they exhibit high basal signaling activity, making them a sensitive model for studying kinase inhibitors and other targeted therapies [4]. Monitoring the rate of proliferation provides critical insights into how a drug candidate modulates T-cell activation and cell cycle progression in the context of leukemia and autoimmune disorders [5].

Other names

Jurkat cell proliferationJurkat cell growthJurkat T-lymphocyte expansionT-cell leukemia cell proliferation

Drugs typically inhibit this process by targeting upstream signaling molecules such as calcineurin, mTOR, or the T-cell receptor (TCR) complex, or by interfering with DNA synthesis and cell cycle checkpoints.